Clinical Trials Directory

Trials / Completed

CompletedNCT00751361

Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial

Prospective, Randomized, Controlled Clinical Study Evaluating the Efficacy of Rheopheresis for Dry Age-Related Macular Degeneration Dry AMD Treatment With Rheopheresis Trial - ART

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
52 (actual)
Sponsor
Apheresis Research Institute · Academic / Other
Sex
All
Age
50 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.

Conditions

Interventions

TypeNameDescription
DEVICERheopheresis / double filtration plasmapheresisRheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.

Timeline

Start date
1998-11-01
Primary completion
2003-01-01
Completion
2003-01-01
First posted
2008-09-11
Last updated
2008-09-11

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00751361. Inclusion in this directory is not an endorsement.

Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial (NCT00751361) · Clinical Trials Directory